Talzenna and Xtandi Win FDA Approval for Earlier HRR-Mutated Metastatic Prostate Cancer, With Anemia the Key Trade-Off
The FDA approved talazoparib with enzalutamide for HRR-mutated, hormone-sensitive metastatic prostate cancer after TALAPRO-3 showed slower progression, though survival remains uncertain and anemia is common.
Medical Daily ·